

8-K
1
c74301e8vk.txt
FORM 8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 28, 2003

COMMISSION FILE NUMBER 1-12584

~~DELAWARE~~ ~~SHEFFIELD PHARMACEUTICALS, INC.~~ ~~13-3808303~~
(State of other jurisdiction of (Exact name of registrant as specified (I.R.S. Employer
incorporation or organization) in its charter) Identification No.)

~~3136 Winton Road South, Suite 201, Rochester, New York~~ ~~14623~~

~~(Address of principal executive officers)~~ ~~(Zip Code)~~

~~Registrant's telephone number, including area code (585) 292-0310~~

~~14528 South Outer Forty Road, Suite 205, St. Louis, Missouri~~ ~~63017~~

~~(Former name or former address, if changed since last report)~~

ITEM 5. OTHER EVENTS

~~On January 24, 2003, Sheffield Pharmaceuticals, Inc., a Delaware corporation, issued a press release, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.~~

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

~~(c) Exhibits~~

~~Exhibit Number Description~~

99.3 Press Release dated January 24, 2003 issued by Sheffield
Pharmaceuticals, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized:

SHEFFIELD PHARMACEUTICALS, INC.

Dated: January 28, 2003 By: /s/ Scott A. Hoffmann

Scott A. Hoffmann

Vice President and Chief Financial Officer